I read with great interest the recent article by Wu et al in a recent issue of your esteemed journal . The article is highly thought provoking. Interestingly, the past few years have seen the emergence of data that points towards the fact that annexin 1 (ANXA1) plays a significant role in systemic carcinogenesis besides its role in the pathogenesis of breast cancers.
For instance, ANXA1 enhances metastasis in urothelial carcinomas . Similar effects are seen in laryngeal carcinomas where ANXA1 plays a modulatory role in tumor growth as is evident by inhibition of tumor growth in Hep-2 human larynx epidermoid carcinoma cell lines . Similarly, nearly 70% of undifferentiated thyroid carcinomas demonstrate attenuated expression of ANXA1 . On the contrary, up regulation of the protein is seen in papillary thyroid carcinomas.
Similarly, over expression of ANXA1 is seen in nearly 85 % of pancreatic ductal adenocarcinomas . Simultaneously, decreased differentiation is seen in pancreatic adenocarcinomas that demonstrate accentuated expression of ANXA1. Similarly, ANXA1 is expressed along with peroxiredoxin 2 in the saliva of oral cancer patients . Hairy cell leukemia also exhibits up regulation of ANXA1. In fact, ANXA1 serves as a remarkably specific test for hairy cell leukemia . Interestingly, agents such as eurycomanone modulate ANXA1 levels and affect tumor growth in cancers such as pulmonary carcinomas .
Clearly, ANXA1 has a major role to play in tumor growth. Further, large scale studies are needed to further elaborate its effects.